Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11285140 Piperidin-4-yl azetidine derivatives as JAK1 inhibitors

Overview Structured Data Issues Contributors Activity

Is a

Patent attributes

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Patent Inventor Names

Chu-Biao Xue0

Taisheng Huang0

Date of Patent

March 29, 2022

Patent Application Number

16878281

Date Filed

May 19, 2020

Patent Citations

US Patent 10166191 Sustained-release dosage forms of ruxolitinib

US Patent 10398699 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors

0

US Patent 10513522 Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors

0

US Patent 10561616 Sustained release dosage forms for a JAK1 inhibitor

US Patent 10639310 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors

US Patent 10695337 Piperidin-4-yl azetidine derivatives as JAK1 inhibitors

US Patent 10640506 Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidines derivatives as JAK inhibitors

0

US Patent 10766900 Baricitinib intermediate, method for forming Baricitinib intermediate, and method for preparing Baricitinib or pharmaceutically acceptable salt thereof

...

Patent Citations Received

US Patent 12071439 Process and intermediates for preparing a JAK inhibitor

0

US Patent 11576864 Sustained-release dosage forms of ruxolitinib

US Patent 11744832 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors

US Patent 11337927 Sustained-release dosage forms of ruxolitinib

0

US Patent 11833155 Combination therapy for treatment of myeloproliferative neoplasms

0

US Patent 11905292 Process and intermediates for preparing a JAK inhibitor

0

US Patent 11992490 Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)

0

US Patent 11576865 Sustained-release dosage forms of ruxolitinib

Patent Primary Examiner

CPC Code

The present invention provides piperidin-4-yl azetidine derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase 1 (JAK1) and are useful in the treatment of diseases related to the activity of JAK1 including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11285140 Piperidin-4-yl azetidine derivatives as JAK1 inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.